CompanyHCM HMDCFNasdaq, OTCHong Kong

Hutchmed

Hutchmed discovers and develops targeted therapies and immunotherapies for cancer and immunological diseases.

SEC EDGAR ClinicalTrials.gov hutch-med.com

6-KSep 29Latest SEC filing, period to Sep 29

Sep 29Latest story

September 2026

HUTCHMED, AstraZeneca file US NDA for Orpathys plus Tagrisso in MET-driven lung cancer

Sep 29Regulatory decisionAstraZeneca Hutchmed

HUTCHMED begins global Phase Ia trial of HMPL-A830 in solid tumors after GSK licensing deal

Sep 28Trial updateHMPL-A830 Hutchmed

HUTCHMED details ESMO 2026 slots for SAFFRON, SANOVO Phase III lung cancer data

Sep 24PublicationAstraZeneca Hutchmed

HUTCHMED licenses HMPL-A830 to GSK; source cites both $1.295B and $1.185B totals

Sep 3Quarterly updateHMPL-A830 Hutchmed

August 2026

HUTCHMED wins NMPA approval for ATLED in FGFR2-altered bile duct cancer

Aug 28Regulatory decisionHutchmed

HUTCHMED discloses insolvency of company linked to its chairman

Aug 18PeopleHutchmed

HUTCHMED and AstraZeneca report positive Phase III SAFFRON data in EGFR-mutated lung cancer

Aug 17Clinical readoutAstraZeneca Hutchmed

July 2026

HUTCHMED posts H1 2026 revenue of $278.3M as China sales rebound and ATTC pipeline advances

Jul 30Quarterly updateHutchmed

Hutchmed registers first-in-human Phase I/IIa trial of HMPL-A830 in solid tumors

Jul 22Trial updateHMPL-A830 Hutchmed

Hutchmed completes Phase 1 drug interaction study for HMPL-453 tartrate tablets

Jul 13Trial updateHutchmed

HUTCHMED wins NMPA approval for Orpathys in MET-amplified gastric cancer

Jul 2Regulatory decisionAstraZeneca Hutchmed

June 2026

Hutchmed sets July 30, 2026 date for first-half financial results

Jun 30Quarterly updateHutchmed